1 Min Read
NEW YORK, March 28 (Reuters) - Oncolytics Biotech Inc : * Oncolytics Biotech U.S.-listed shares up 9 percent to $3.26 in premarket after lung cancer drug meets main goal of mid-stage study
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.